Partnering opportunities

A DC subset with superior antigen-presenting capability, engineered with a proprietary CAR design for immunotherapy.

A novel small molecule targeting a key susceptibility in MYC driven cancers.

A first-in-class small molecule inhibitor for blood cancers including AML.

An optimised human biologic targeting EphA10 for aggressive solid cancers​.

A new therapy for global prevention of hemolytic disease of the newborn

Developing a first-in-class, anti-NINJ1 therapy for cell death associated diseases.

Targeting inflammatory cytokine signalling in autoimmune disease

Degradation of c-Rel for treating chronic autoimmune inflammatory disease.

A novel lung macrophage-targeted LNP therapy for COPD and respiratory diseases.

A media cocktail and culture system for in vitro human haematopoiesis.

Oral therapeutic targeting coronavirus Mpro; potential to minimise progression to severe disease and post-acute sequelae of COVID-19 (PASC / Long COVID).

Human antibodies targeting specifc bacterial glycans to treat antibiotic resistant gram negative bacterial infections.

Rapid and accurate TSAT testing for diagnosis and treatment of iron deficiency.

A high throughput diagnostic for relapsing liver malaria.

A high-throughput laboratory-based diagnostic for detecting hidden or cryptic liver stage Plasmodium vivax infections.

Using an epigenetic approach to turn on genes, the absence of which causes Prader Willi Syndrome, a devistating neurodevelopment disorder

A small molecule inhibitor of Bax-mediated apoptosis in dopaminergic neurons to prevent and treat Parkinson’s Disease.

Developing a small molecule activator of Pink1 for treatment of Parkinson’s Disease.

An effective and affordable plunge freezing device for cryogenic electron microscopy.